ABIVAX is trading 4.22% higher at €80.35 on October 9, 2026, amid stronger biotech-sector sentiment, with no clear company-specific announcement explaining the move.
- Supplied context reports XBI up 2.50%, supported by biotech IPOs and deal activity; this is sector context, not proof of an ABIVAX-specific catalyst.
- The company’s latest listed update was its September 30 announcement about obefazimod presentations at UEG Week, scheduled for October 17–20.
- Recent company coverage noted sustained selling pressure and technical weakness.